Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview

Ponziani, Francesca Romana; Gasbarrini, Antonio; Pompili, Maurizio; Burra, Patrizia; Fagiuoli, Stefano

doi:10.1016/j.transproceed.2010.09.102

Cited by 20 publications

(14 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have examined the efficacy of pegylated IFN and RBV for patients with recurrent hepatitis, of whom 16% to 33% developed LC 58. SVR rates were 32% to 40% for patients with HCV genotype 1 infection and 50% to 100% for patients with genotype 2 or 3 infection.…”

Section: Daa Therapy For Lc Patientsmentioning

confidence: 99%

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis

Toshikuni

2017

Gut and Liver

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection may eventually lead to liver cirrhosis (LC), a condition associated with a high risk of liver failure and hepatocellular carcinoma. Although interferon (IFN)-based therapy has made substantial contributions to the management of HCV-infected patients, this therapy has limitations for LC patients in terms of eligibility, tolerability, relatively low and high rates of sustained virological response (SVR), and serious adverse events. Therapy with newly developed direct-acting antiviral agents (DAAs) can overcome these limitations in IFN-based therapy. Recent phase 3 trials have demonstrated that DAA therapy achieved high SVR rates (more than 90% for genotype 1; 80% to 90% for genotype 2; 60% to 70% for genotype 3) for compensated LC patients, with high tolerability and relatively low rates of serious adverse events. Furthermore, trials have suggested that DAA therapy can be used for the treatment of decompensated LC patients as well as pretransplant and post-transplant LC patients. In this article, we review the current status of DAA therapy for HCV-related LC patients.

show abstract

Section: Daa Therapy For Lc Patientsmentioning

confidence: 99%

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis

Toshikuni

2017

Gut and Liver

View full text Add to dashboard Cite

show abstract

“…If not successfully treated, CHC can lead to serious complications such as cirrhosis and hepatocellular carcinoma . CHC is currently the leading indication for liver transplantation in the United States …”

Section: Introductionmentioning

confidence: 99%

The pharmacokinetics of peginterferon alfa‐2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C

Brennan

Morcos

Wang

et al. 2012

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Additionally, the post‐LT recurrence of HCV infections is one of the major causes of morbidity and allograft loss after LT 11,14–16. Because the outcomes of post‐LT therapy with the classic antiviral agents PEG‐IFN and RBV are at most moderate with respect to a sustained virological response (SVR), LT patients constitute one of the classic difficult‐to‐treat groups 16–22. Newly introduced protease inhibitor (PI)–based triple therapy now offers promising perspectives for the management of LT patients, although TVR is not yet approved for use in LT patients.…”

mentioning

confidence: 99%

Telaprevir‐based triple therapy in liver transplant patients with hepatitis C virus: A 12‐week pilot study providing safety and efficacy data

Werner¹,

Egetemeyr²,

Lauer³

et al. 2012

Liver Transpl

View full text Add to dashboard Cite

After liver transplantation (LT), the management of recurrent hepatitis C virus (HCV) infections still remains a major challenge. In HCV genotype 1 patients not undergoing transplantation, the introduction of protease inhibitor (PI)-based regimens has increased the sustained virological response rate significantly. This pilot study investigated both the safety and efficacy of telaprevir (TVR)-based triple therapy in HCV-infected LT patients with a special emphasis on drug-drug interactions between immunosuppressants and PIs. Safety and efficacy data were gathered for 12 weeks for 9 HCV-infected LT patients who were treated with a combination of TVR, pegylated interferon, and ribavirin (RBV) in parallel with immunosuppressive drugs such as tacrolimus (TAC; n ¼ 4), cyclosporine A (CSA; n ¼ 4), and sirolimus (SIR; n ¼ 1). Seven of the transplant patients completed the 12 weeks of triple therapy. At week 4, 4 of the patients were found to be HCV RNA-negative, and importantly, 8 were found to be negative at week 12. During the 12-week course of triple therapy, short-term measurements of immunosuppressant trough levels required individual dose reductions in all patients (CSA, 2.5-fold; SIR, 7-fold; and TAC, 22-fold). Furthermore, two-thirds of the patients exhibited hematological side effects requiring RBV dose reductions, the administration of erythropoietin, or even blood transfusions. In conclusion, this pilot study provides evidence showing that TVR-based triple therapy is effective within the first 4 to 12 weeks in LT patients suffering from HCV genotype 1 recurrence, and it also provides evidence showing that drug-drug interactions between TVR and immunosuppressants can be handled appropriately through the close monitoring of trough levels and adequate dosage adjustments.

show abstract

Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview

Cited by 20 publications

References 91 publications

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis

The pharmacokinetics of peginterferon alfa‐2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C

Telaprevir‐based triple therapy in liver transplant patients with hepatitis C virus: A 12‐week pilot study providing safety and efficacy data

Contact Info

Product

Resources

About